Compare GSIT & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSIT | CERS |
|---|---|---|
| Founded | 1995 | 1991 |
| Country | United States | United States |
| Employees | 125 | N/A |
| Industry | Semiconductors | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.0M | 276.0M |
| IPO Year | 2004 | 1996 |
| Metric | GSIT | CERS |
|---|---|---|
| Price | $7.54 | $2.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | $25,122,000.00 | ★ $51,326,000.00 |
| Revenue This Year | N/A | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 22.44 | ★ 30.68 |
| 52 Week Low | $2.82 | $1.15 |
| 52 Week High | $18.14 | $3.15 |
| Indicator | GSIT | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 54.87 |
| Support Level | $6.99 | $1.84 |
| Resistance Level | $8.99 | $2.91 |
| Average True Range (ATR) | 0.84 | 0.17 |
| MACD | -0.25 | -0.03 |
| Stochastic Oscillator | 9.73 | 43.55 |
GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.